Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263873 | 0.82 | LPL (0.31) | — | |
| SCHEMBL10045640 | 0.82 | NPC1 (0.38) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL14820964 | 0.81 | LPL (0.33) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL1637147 | 0.81 | NPC1 (0.37) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL15028119 | 0.81 | NPC1 (0.37) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL2262622 | 0.77 | HIF1A (0.31) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL12263947 | 0.75 | NPC1 (0.38) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL21888321 | 0.75 | KDM4E (0.33) | — | |
| SCHEMBL27350800 | 0.74 | ALDH1A1 (0.44) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL22328895 | 0.74 | JAK2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8072137-B2 | Fused heterocyclic compound and organic light emitting device | CANON KABUSHIKI KAISHA (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20090121625-A1 | FUSED HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090121625-A1 | FUSED HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE | TYR, CRY1, LAGE3 | NPC1 2223/4885ALDH1A1 145/4885PLA2G1B 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.